Previous 10 | Next 10 |
Eiger BioPharmaceuticals, Inc. (EIGR) Q4 2021 Earnings Conference Call March 10, 2022 4:30 P.M. ET Company Participants Sri Ryali - Chief Financial Officer David Cory - President and Chief Executive Officer Ingrid Choong - Senior Vice President-Clinical Development Eldon Mayer - Chief Commerc...
Eiger BioPharmaceuticals press release (NASDAQ:EIGR): Q4 GAAP EPS of -$0.64 misses by $0.01. Revenue of $3.36M misses by $0.03M. For further details see: Eiger BioPharmaceuticals GAAP EPS of -$0.64 misses by $0.01, revenue of $3.36M misses by $0.03M
Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update PR Newswire PALO ALTO, Calif. , March 10, 2022 /PRNewswire/ -- Phase 3 COVID-19 TOGETHER (Lambda) Study Data in March 2022 ...
Eiger BioPharmaceuticals to Host Conference Call for Fourth Quarter & Full Year 2021 Financial Results and Business Update on Thursday, March 10 Eiger BioPharmaceuticals to Host Conference Call for Fourth Quarter & Full Year 2021 Financial Results and Business Update on ...
Eiger BioPharmaceuticals Announces Outlook and Planned 2022 Catalysts and Milestones - Phase 3 HDV D-LIVR (Lonafarnib) Study Topline Data Planned by End of 2022 - Phase 3 HDV LIMT-2 (Peginterferon Lambda) Study Enrolling and Dosing - Phase 3 COVID-19 TOGETHER (Peginterfe...
Eiger BioPharmaceuticals to Present at H.C. Wainwright BioConnect 2022 Virtual Conference PR Newswire PALO ALTO, Calif. , Jan. 3, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the d...
Eiger's D-LIVR trial will readout in end-2022. EIGR is the leading developer of a treatment for hepatitis D. The company is adequately funded. For further details see: Eiger Pharma: HDV Approval In 2023 Is A Major Catalyst
Eiger BioPharmaceuticals Announces First Patient Enrolled in LIMT-2: A Phase 3 Study of Peginterferon Lambda in Patients with Chronic Hepatitis Delta Virus (HDV) Infection PR Newswire PALO ALTO, Calif. , Dec. 21, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals...
Eiger BioPharmaceuticals Announces Second Positive Interim Analysis and Continuation of Dosing of Peginterferon Lambda in Phase 3 TOGETHER Study of Newly Diagnosed COVID-19 Patients - Interim analysis of 1,003 patients, randomized to Peginterferon Lambda vs placebo - Variant...
For 2022, I am going to focus on those companies poised to benefit from the tragic COVID-19 pandemic. I maintain that SARS-CoV-2 will be with us for a long time. As for the proposed drug price legislation in BBBA, it would impact biologics (high cost medications) only near the end of ...
News, Short Squeeze, Breakout and More Instantly...
Eiger BioPharmaceuticals Inc. Company Name:
EIGR Stock Symbol:
NASDAQ Market:
Eiger BioPharmaceuticals Inc. Website:
A look at the top 10 most actives in the United States Nikola Corporation (NKLA) rose 6.5% to $0.95 on volume of 182,734,103 shares WiSA Technologies Inc. (WISA) fell 3.3% to $0.0235 on volume of 160,634,740 shares PROSHARES TRUST (SQQQ) rose 4.7% to $11.12 on volume of 151,373,755 shares...
A look at the top 10 most actives in the United States Sunshine Biopharma Inc. (SBFM) rose 76.0% to $0.1065 on volume of 290,483,542 shares CXApp Inc. (CXAI) rose 151.0% to $6.15 on volume of 236,739,031 shares Nikola Corporation (NKLA) fell 1.0% to $1.03 on volume of 123,276,764 shares ...
Announces “Stalking Horse” Agreement for the Sale of Zokinvy ® (lonafarnib) Patient Access to Zokinvy ® to Continue Uninterrupted PALO ALTO, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR) today ...